Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
81.18
-0.52 (-0.64%)
May 28, 2026, 1:00 PM EDT - Market open
Kymera Therapeutics Stock Forecast
Stock Price Forecast
According to 24 analysts polled by S&P Global, Kymera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $118.27. The average 1-year stock price forecast is 45.69% higher than the current stock price, while the lowest is $91 (+12.10%) and the highest is $140 (+72.46%).
Price Target: $118.27 (+45.69%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 17 | 17 | 17 | 17 | 18 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 23 | 23 | 23 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $106 | Buy | Maintains | $106 | +30.57% | May 20, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $134 | Buy | Maintains | $134 | +65.07% | May 4, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 1, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $125 | Buy | Reiterates | $125 | +53.98% | May 1, 2026 |
Financial Forecast
Revenue This Year
92.15M
from 39.21M
Increased by 135.00%
Revenue Next Year
39.31M
from 92.15M
Decreased by -57.34%
EPS This Year
-3.47
from -3.69
EPS Next Year
-4.30
from -3.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 135.5M | 102.3M | ||||||
| Avg | 92.1M | 39.3M | ||||||
| Low | 48.0M | -12.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 245.4% | 11.0% | ||||||
| Avg | 135.0% | -57.3% | ||||||
| Low | 22.5% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.82 | -3.37 | ||||||
| Avg | -3.47 | -4.30 | ||||||
| Low | -4.02 | -5.13 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.